201 related articles for article (PubMed ID: 28230637)
1. mTOR Inhibition and Cardiovascular Diseases: Cardiac Hypertrophy.
Paoletti E
Transplantation; 2018 Feb; 102(2S Suppl 1):S41-S43. PubMed ID: 28230637
[TBL] [Abstract][Full Text] [Related]
2. Regression of left ventricular hypertrophy in kidney transplant recipients: the potential role for inhibition of mammalian target of rapamycin.
Paoletti E; Cannella G
Transplant Proc; 2010 Nov; 42(9 Suppl):S41-3. PubMed ID: 21095451
[TBL] [Abstract][Full Text] [Related]
3. mTOR Inhibition and Clinical Transplantation: Kidney.
Flechner SM
Transplantation; 2018 Feb; 102(2S Suppl 1):S17-S18. PubMed ID: 28230636
[No Abstract] [Full Text] [Related]
4. mTOR Inhibition and Kidney Diseases.
Ma MKM; Yung S; Chan TM
Transplantation; 2018 Feb; 102(2S Suppl 1):S32-S40. PubMed ID: 29369972
[TBL] [Abstract][Full Text] [Related]
5. mTOR Inhibition and Clinical Transplantation: Pancreas and Islet.
Berney T; Andres A; Toso C; Majno P; Squifflet JP
Transplantation; 2018 Feb; 102(2S Suppl 1):S30-S31. PubMed ID: 28230643
[TBL] [Abstract][Full Text] [Related]
6. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial.
Paoletti E; Amidone M; Cassottana P; Gherzi M; Marsano L; Cannella G
Am J Kidney Dis; 2008 Aug; 52(2):324-30. PubMed ID: 18585837
[TBL] [Abstract][Full Text] [Related]
7. Mammalian Target of Rapamycin Inhibitor Monotherapy: Efficacy in Renal Transplantation.
Franco A; Más-Serrano P; Perez Contreras J; Jiménez L; Rodriguez D; Olivares J
Transplant Proc; 2015 Oct; 47(8):2364-7. PubMed ID: 26518928
[TBL] [Abstract][Full Text] [Related]
8. The impact of mTOR inhibitors in the regression of left ventricular hypertrophy in elderly kidney transplant recipients.
David-Neto E; Filho MPM; de Sá ÍJAS; Agena F; de Andrade JL; de Paula FJ
Clin Transplant; 2022 Aug; 36(8):e14742. PubMed ID: 35678134
[TBL] [Abstract][Full Text] [Related]
9. mTOR Inhibition and Clinical Transplantation: Heart.
Zuckermann A; Osorio-Jaramillo E; Aliabadi-Zuckermann AZ
Transplantation; 2018 Feb; 102(2S Suppl 1):S27-S29. PubMed ID: 29369971
[TBL] [Abstract][Full Text] [Related]
10. Conversion therapy to everolimus in renal transplant recipients: results after one year.
Giron F; Baez Y; Niño-Murcia A; Rodríguez J; Salcedo S
Transplant Proc; 2008 Apr; 40(3):711-3. PubMed ID: 18454994
[TBL] [Abstract][Full Text] [Related]
11. Reducing the risk of left ventricular hypertrophy in kidney transplant recipients: the potential role of mammalian target of rapamycin.
Paoletti E; Cannella G
Transplant Proc; 2009; 41(6 Suppl):S3-5. PubMed ID: 19651293
[TBL] [Abstract][Full Text] [Related]
12. The Long Journey of mTOR Inhibitors and the Long Path That Is Still Ahead.
Tedesco Silva H
Transplantation; 2018 Feb; 102(2S Suppl 1):S1-S2. PubMed ID: 29369969
[No Abstract] [Full Text] [Related]
13. mTOR Inhibition and Clinical Transplantation: Liver.
Nashan B
Transplantation; 2018 Feb; 102(2S Suppl 1):S19-S26. PubMed ID: 28230639
[TBL] [Abstract][Full Text] [Related]
14. Use of Everolimus-based Immunosuppression to Decrease Cytomegalovirus Infection After Kidney Transplant.
Malvezzi P; Jouve T; Rostaing L
Exp Clin Transplant; 2016 Aug; 14(4):361-6. PubMed ID: 27041365
[TBL] [Abstract][Full Text] [Related]
15. Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial.
Paoletti E; Marsano L; Bellino D; Cassottana P; Cannella G
Transplantation; 2012 Mar; 93(5):503-8. PubMed ID: 22318246
[TBL] [Abstract][Full Text] [Related]
16. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel.
Kumar J; Bridson JM; Sharma A; Halawa A
Exp Clin Transplant; 2017 Jun; 15(3):241-252. PubMed ID: 27915965
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in Mammalian Target of Rapamycin Inhibitor Use in Heart and Lung Transplantation.
Fine NM; Kushwaha SS
Transplantation; 2016 Dec; 100(12):2558-2568. PubMed ID: 27495747
[TBL] [Abstract][Full Text] [Related]
18. Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients.
Badve SV; Pascoe EM; Burke M; Clayton PA; Campbell SB; Hawley CM; Lim WH; McDonald SP; Wong G; Johnson DW
Clin J Am Soc Nephrol; 2016 Oct; 11(10):1845-1855. PubMed ID: 27445164
[TBL] [Abstract][Full Text] [Related]
19. Clinical evidence on the use of anti-mTOR drugs in renal transplantation.
Hernández D; Martínez D; Gutiérrez E; López V; Gutiérrez C; García P; Cobelo C; Cabello M; Burgos D; Sola E; González-Molina M
Nefrologia; 2011; 31(1):27-34. PubMed ID: 21270910
[TBL] [Abstract][Full Text] [Related]
20. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
Diekmann F; Andrés A; Oppenheimer F
Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
